Zhiyi Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zhiyi Biotech - overview
Established
2013
Location
Guangzhou, Guangdong, China
Primary Industry
Biotechnology
About
Founded in 2013 and based in Guangzhou, Guangzhou Zhiyi Biotechnology Co. , Ltd. , trading as Zhiyi Biotech, operates as a provider of a biopharmaceutical company that focuses on the research and development of next-generation probiotics and live biotherapeutics. The company has been approved more than 10 projects, including National 863 Special Project and Guangdong Provincial Major New Drug Creation Special Project.
It has built a 10,000-square-meter R&D center and pilot plant, including two GMP standard pilot plants. Its SK08(Bacteroides fragilis) was approved for clinical trials in November 2019, Phase II clinical study for safety and tolerability of SK08 has enrolled in 2021. In April 2026, Zhiyi Biotech raised a series C+ funding from Jingyao Fund and Lehong Investment. The company has established a technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients.
The main product, SK08, is an original biopharmaceutical and an in vivo biopharmaceutical developed using a new strain of Bacteroides Fragilis. The SK10 developed by the company can be used for treatment of chemotherapy-associated diarrhea. The company's revenue is generated by providing R&D services in clinical stage of live biotherapeutics (LBPs) and next-generation probiotics (NGPs).
Current Investors
Shenzhen Capital Real Estate Fund, Nantong Jinxin Tongda Investment Management, Guangzhou Shangdong Asset Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.zypharm.com.cn/
Company Stage
Series C
Total Amount Raised
Subscriber access only
Zhiyi Biotech - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.